Skip to content

Obe-cel provides consistent efficacy and safety for relapsed or refractory B-ALL regardless of EMD status
Selina Luger, MD, weighs the promise and challenges of modern ALL care
Advancing care through collaborative science: A European perspective
SOHO 2026 Friday plenary features NIH scientist and aplastic anemia expert Dr. Neal S. Young
Dr. Maddocks previews Friday MCL session at SOHO 2026

Insider Reader Survey

Join SOHO

Follow Us :

Insider Podcast
Society Updates
Resources
Hem/Onc Library
- Cellular Therapy
- Leukemia
  - ALL
  - AML
  - CLL
  - CML
- Lymphoma
  - ABCL
  - IBCL
  - MCL
  - TCL
- MDS
- MPN
- Multiple Myeloma
Community Oncology
- Past Sessions
Meeting News
Multimedia
- Roundtable Discussions
- Video Interviews
Subscribe

About Us

The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.

Join SOHO

Categories

Session sparks debate on whether chemotherapy is needed in ALL care

Cellular Therapy

Session sparks debate on whether chemotherapy is needed in ALL care

Leukemia

Session sparks debate on whether chemotherapy is needed in ALL care

Lymphoma

Session sparks debate on whether chemotherapy is needed in ALL care

Multiple Myeloma

Session sparks debate on whether chemotherapy is needed in ALL care

Myelodysplastic Syndromes

Session sparks debate on whether chemotherapy is needed in ALL care

Myeloproliferative Neoplasms

Contact Info

[email protected] 1.281.364.7387

Follow Us

September 13, 2026

Insider Podcast
Society Updates
Resources
Hem/Onc Library
- Cellular Therapy
- Leukemia
  - ALL
  - AML
  - CLL
  - CML
- Lymphoma
  - ABCL
  - IBCL
  - MCL
  - TCL
- MDS
- MPN
- Multiple Myeloma
Community Oncology
- Past Sessions
Meeting News
Multimedia
- Roundtable Discussions
- Video Interviews
Subscribe

SOHO Insider Hem/Onc Library Leukemia Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia

Elias Jabbour

Section Editor of ALL

Elias Jabbour, MD

The University of Texas
MD Anderson Cancer Center

Acute Lymphoblastic Leukemia News SOHO 2026 Cellular Therapy Leukemia Acute Lymphoblastic Leukemia Meetings / Conferences News

Session sparks debate on whether chemotherapy is needed in ALL care

by Elias Jabbour, MD
September 7, 2026
0 Comments

Acute Lymphoblastic Leukemia News Leukemia News SOHO 2026 Cellular Therapy Leukemia Acute Lymphoblastic Leukemia News Video Interviews

Dr. DiPersio previews the SOHO 2026 ALL session to be held on Wednesday, September 9

by SOHO Insider Editors
September 2, 2026
0 Comments

Doctor holding an ipad

Acute Lymphoblastic Leukemia News SOHO 2026 Leukemia Acute Lymphoblastic Leukemia Meetings / Conferences News

TKI discontinuation possible in Ph+ ALL following treatment with blinatumomab and ponatinib

by Kerri Fitzgerald
September 1, 2026
0 Comments

Jabbour

EHA 2026 ASCO 2026 Leukemia Acute Lymphoblastic Leukemia Chronic Myeloid Leukemia Video Interviews

ASCO and EHA 2026 updates on the third-gen TKI olverembatinib

by SOHO Insider Editors
August 10, 2026
0 Comments

A close up of a globe with a network of lines surrounding it. Concept of interconnectedness and the vastness of the world

Leukemia Acute Lymphoblastic Leukemia Acute Myeloid Leukemia News

Global KMT2A MRD testing launched for AML,ALL

by SOHO Insider Editors
August 10, 2026
0 Comments

Community Oncology News Trending now Leukemia Acute Lymphoblastic Leukemia Lymphoma Aggressive B-Cell Lymphomas Video Interviews

Dr. Gwen Nichols: Addressing funding gaps in blood cancer research

by SOHO Insider Editors
August 7, 2026
0 Comments

Insider_YT_Ponce_400x400

EHA 2026 Leukemia Acute Lymphoblastic Leukemia Lymphoma Aggressive B-Cell Lymphomas Meetings / Conferences Multiple Myeloma Video Interviews

Doris Ponce, MD, discusses bone health findings with axatilimab in chronic GVHD

by SOHO Insider Editors
August 3, 2026
0 Comments

Silver,Spring,,Md,,Usa,-,June,25,,2022:,The,Fda

Leukemia Acute Lymphoblastic Leukemia News

FDA approves allogeneic regulatory T cell-based immunotherapy for hematologic malignancies

by SOHO Insider Editors
July 5, 2026
0 Comments

EHA 2026 Cellular Therapy Leukemia Acute Lymphoblastic Leukemia Meetings / Conferences

Nanobody-based anti-CD5 CAR T agent improves efficacy in relapsed or refractory T-cell ALL

by Patrick Daly
June 30, 2026
0 Comments

Insider_YT_Feature_Pannunzio_CLFR2_400x400[15]

AACR 2026 Acute Lymphoblastic Leukemia News Video Interviews

Nicholas Pannunzio, PhD, discusses Ph-like ALL and CRLF2 rearrangement

by SOHO Insider Editors
June 22, 2026
0 Comments

1
2
3
...
5

Top Categories

Cellular Therapy

82

Leukemia

133

Lymphoma

141

Multiple Myeloma

120

Myelodysplastic Syndromes

49

Myeloproliferative Neoplasms

36

POPULAR NEWS

The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.

About

About Us / Editorial Board

Advertising

Contact Us

Support SOHO

Categories

Nicholas Pannunzio, PhD, discusses Ph-like ALL and CRLF2 rearrangement

Cellular Therapy

Nicholas Pannunzio, PhD, discusses Ph-like ALL and CRLF2 rearrangement

Leukemia

Nicholas Pannunzio, PhD, discusses Ph-like ALL and CRLF2 rearrangement

Lymphoma

Nicholas Pannunzio, PhD, discusses Ph-like ALL and CRLF2 rearrangement

Multiple Myeloma

Nicholas Pannunzio, PhD, discusses Ph-like ALL and CRLF2 rearrangement

Myelodysplastic Syndromes

Nicholas Pannunzio, PhD, discusses Ph-like ALL and CRLF2 rearrangement

Myeloproliferative Neoplasms

Subscribe

Recent Posts

Doctor holding an ipad

Obe-cel provides consistent efficacy and safety for relapsed or refractory B-ALL regardless of EMD status

Selina Luger, MD, weighs the promise and challenges of modern ALL care

Advancing care through collaborative science: A European perspective

Copyright © 2026 Society of Hematologic Oncology, All rights reserved.